Solasta Ventures
Home Approach Portfolio
News Team Hatchery Contact
HomeApproachPortfolio
Solasta Ventures
NewsTeamHatcheryContact
CARISMA THERAPEUTICS COMPLETES SERIES B FUNDING FOR $47 MILLION TO ADVANCE DEVELOPMENT OF NOVEL CAR-MACROPHAGE IMMUNOTHERAPIES
Nia JulianJanuary 7, 2021
Facebook0 Twitter Pinterest0 0 Likes
Previous

Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer

Nia JulianFebruary 11, 2021
Next

Redwood City-based Seer's stock nearly tripled in IPO, valuing company at over $3B

Nia JulianDecember 8, 2020

© 2020 Solasta Ventures. All Rights Reserved.